Eddie Luidy Imada

Eddie Luidy Imada

Auto-generated profile, based on publicly available information

Eddie Luidy Imada

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Research in Microbiology
Verified
Journal Article
Closed access
EIEddie Luidy Imada
Eddie Luidy Imada
ASAmanda Alves de Paiva Rolla dos Santos
Amanda Alves de Paiva Rolla dos Santos
AOAndre Luiz Martinez de Oliveira
Andre Luiz Martinez de Oliveira
Mariangela HungriaMariangela Hungria
Mariangela Hungria
ERElisete Pains Rodrigues
Elisete Pains Rodrigues

4 June 2024 in Cancer Research
Verified
Journal Article
Open access
NBNadia Boufaied
Nadia Boufaied
PCPaolo Chetta
Paolo Chetta
THTarek Hallal
Tarek Hallal
Stefano CacciatoreStefano Cacciatore
Stefano Cacciatore
DLDaniela Lalli
Daniela Lalli
GZGiorgia Zadra
Giorgia Zadra
Cancer cells exhibit metabolic plasticity to meet oncogene-driven dependencies while coping with nutrient availability. A better understanding of how systemic metabolism impacts the accumulation of metabolites that reprogram the tumor microenvironment (TME) and drive cancer could facilitate development of precision nutrition approaches. Using the Hi-MYC prostate cancer mouse model, we demonstrated that an obesogenic high-fat diet (HFD) rich in saturated fats accelerates the development of c-MYC–driven invasive prostate cancer through metabolic rewiring. Although c-MYC modulated key metabolic pathways, interaction with an obesogenic HFD was necessary to induce glycolysis and lactate accumulation in tumors. These metabolic changes were associated with augmented infiltration of CD206+ and PD-L1+ tumor-associated macrophages (TAM) and FOXP3+ regulatory T cells, as well as with the activation of transcriptional programs linked to disease progression and therapy resistance. Lactate itself also stimulated neoangiogenesis and prostate cancer cell migration, which were significantly reduced following treatment with the lactate dehydrogenase inhibitor FX11. In patients with prostate cancer, high saturated fat intake and increased body mass index were associated with tumor glycolytic features that promote the infiltration of M2-like TAMs. Finally, upregulation of lactate dehydrogenase, indicative of a lactagenic phenotype, was associated with a shorter time to biochemical recurrence in independent clinical cohorts. This work identifies cooperation between genetic drivers and systemic metabolism to hijack the TME and promote prostate cancer progression through oncometabolite accumulation. This sets the stage for the assessment of lactate as a prognostic biomarker and supports strategies of dietary intervention and direct lactagenesis blockade in treating advanced prostate cancer. Significance: Lactate accumulation driven by high-fat diet and MYC reprograms the tumor microenvironment and promotes prostate cancer progression, supporting the potential of lactate as a biomarker and therapeutic target in prostate cancer. See related commentary by Frigo, p. 1742

24 April 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
CZClaudio Zanettini
Claudio Zanettini
MOMohamed Omar
Mohamed Omar
WDWikum Dinalankara
Wikum Dinalankara
EIEddie Luidy Imada
Eddie Luidy Imada
ECElizabeth Colantuoni
Elizabeth Colantuoni
LMLuigi Marchionni
Luigi Marchionni
The COVID-19 mortality rate is higher in the elderly and in those with pre-existing chronic medical conditions. The elderly also suffer from increased morbidity and mortality from seasonal influenza infections; thus, an annual influenza vaccination is recommended for them. In this study, we explore a possible county-level association between influenza vaccination coverage in people aged 65 years and older and the number of deaths from COVID-19. To this end, we used COVID-19 data up to 14 December 2020 and US population health data at the county level. We fit quasi-Poisson regression models using influenza vaccination coverage in the elderly population as the independent variable and the COVID-19 mortality rate as the outcome variable. We adjusted for an array of potential confounders using different propensity score regression methods. Results show that, on the county level, influenza vaccination coverage in the elderly population is negatively associated with mortality from COVID-19, using different methodologies for confounding adjustment. These findings point to the need for studying the relationship between influenza vaccination and COVID-19 mortality at the individual level to investigate any underlying biological mechanisms.

26 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
CZClaudio Zanettini
Claudio Zanettini
MOMohamed Omar
Mohamed Omar
WDWikum Dinalankara
Wikum Dinalankara
EIEddie Luidy Imada
Eddie Luidy Imada
ECElizabeth Colantuoni
Elizabeth Colantuoni
LMLuigi Marchionni
Luigi Marchionni
COVID-19 mortality rate is higher in the elderly and in those with preexisting chronic medical conditions. The elderly also suffer from increased morbidity and mortality from seasonal influenza infection, and thus annual influenza vaccination is recommended for them. In this study, we explore a possible area-level association between influenza vaccination coverage in people aged 65 years and older and the number of deaths from COVID-19. To this end, we used COVID-19 data until June 10, 2020 together with population health data for the United States at the county level. We fit quasi-Poisson regression models using influenza vaccination coverage in the elderly population as the independent variable and the number of deaths from COVID-19 as the outcome variable. We adjusted for a wide array of potential confounding variables using both county-level generalized propensity scores for influenza vaccination rates, as well as direct adjustment. Our results suggest that influenza vaccination coverage in the elderly population is negatively associated with mortality from COVID-19. This finding is robust to using different analysis periods, different thresholds for inclusion of counties, and a variety of methodologies for confounding adjustment. In conclusion, our results suggest a potential protective effect of the influenza vaccine on COVID-19 mortality in the elderly population. The significant public health implications of this possibility point to an urgent need for studying the relationship between influenza vaccination and COVID-19 mortality at the individual level, to investigate both the epidemiology and any underlying biological mechanism.

20 February 2020 in Genome Research
Verified
Journal Article
Open access
PDF file
EIEddie Luidy Imada
Eddie Luidy Imada
DSDiego Fernando Sanchez
Diego Fernando Sanchez
LCLeonardo Collado-Torres
Leonardo Collado-Torres
CWChristopher Wilks
Christopher Wilks
TMTejasvi Matam
Tejasvi Matam
LMLuigi Marchionni
Luigi Marchionni
Long noncoding RNAs (lncRNAs) have emerged as key coordinators of biological and cellular processes. Characterizing lncRNA expression across cells and tissues is key to understanding their role in determining phenotypes, including human diseases. We present here FC-R2, a comprehensive expression atlas across a broadly defined human transcriptome, inclusive of over 109,000 coding and noncoding genes, as described in the FANTOM CAGE-Associated Transcriptome (FANTOM-CAT) study. This atlas greatly extends the gene annotation used in the originalrecount2resource. We demonstrate the utility of the FC-R2 atlas by reproducing key findings from published large studies and by generating new results across normal and diseased human samples. In particular, we (a) identify tissue-specific transcription profiles for distinct classes of coding and noncoding genes, (b) perform differential expression analysis across thirteen cancer types, identifying novel noncoding genes potentially involved in tumor pathogenesis and progression, and (c) confirm the prognostic value for several enhancer lncRNAs expression in cancer. Our resource is instrumental for the systematic molecular characterization of lncRNA by the FANTOM6 Consortium. In conclusion, comprised of over 70,000 samples, the FC-R2 atlas will empower other researchers to investigate functions and biological roles of both known coding genes and novel lncRNAs.

26 July 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
EIEddie Luidy Imada
Eddie Luidy Imada
DSDiego Fernando Sanchez
Diego Fernando Sanchez
WDWikum Dinalankara
Wikum Dinalankara
TVThiago Vidotto
Thiago Vidotto
EEEricka M. Ebot
Ericka M. Ebot
LMLuigi Marchionni
Luigi Marchionni
Background: PTEN is the most frequently lost tumor suppressor in primary prostate cancer (PCa) and its loss is associated with aggressive disease. However, the transcriptional changes associated with PTEN loss in PCa have not been described in detail. In this study, we highlight the transcriptional changes associated with PTEN loss in PCa.Methods: Using a meta-analysis approach, we leveraged two large PCa cohorts with experimentally validated PTEN and ERG status by Immunohistochemistry (IHC), to derive a transcriptomic signature ofPTENloss, while also accounting for potential confounders due toERGrearrangements. This signature was expanded to lncRNAs using the TCGA quantifications from the FC-R2 expression atlas.Results: The signatures indicate a strong activation of both innate and adaptive immune systems uponPTENloss, as well as an expected activation of cell-cycle genes. Moreover, we made use of our recently developed FC-R2 expression atlas to expand this signature to include many non-coding RNAs recently annotated by the FANTOM consortium. Highlighting potential novel lncRNAs associated with PTEN loss and PCa progression.Conclusion: We created a PCa specific signature of the transcriptional landscape ofPTENloss that comprises both the coding and an extensive non-coding counterpart, highlighting potential new players in PCa progression. We also show that contrary to what is observed in other cancers, PTEN loss in PCa leads to increased activation of the immune system. These findings can help the development of new biomarkers and help guide therapy choices.